Sankyo to Launch Osteoporosis Treatment Drug in Europe.Tokyo, Japan, July 19, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Daiichi Sankyo Europe GmbH, a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Sankyo Co. Ltd., have agreed with Eli Lilly on the launch of EVISTA (raloxifene), a new drug that helps prevent osteoporosis and can only be taken after menopause. Raloxifene is a selective estrogen receptor modulator se·lec·tive estrogen receptor modulator n. Abbr. SERM A nonsteroidal compound, such as raloxifene or tamoxifen, designed to mimic the effect of estrogen on a specific tissue or body part by binding only to that part's estrogen receptors. , specifically developed to maintain beneficial estrogenic activity on bone and lipids and antiestrogenic activity on endometrial endometrial /en·do·me·tri·al/ (en?do-me´tre-il) pertaining to the endometrium. endometrial, n relating to the end-ometrium or cavity of the uterus. and breast tissue. It slows bone loss and slightly increases normal bone growth. Because of its tissue selectivity, raloxifene may have fewer side effects than are typically observed with estrogen therapy including vaginal bleeding and breast tenderness. There still needs more proof that raloxifene can also prevent bone fractures or lowers the risk of heart disease. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion